When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...
A newer type of prostate cancer scan called 64 Cu-SAR-bisPSMA found more than twice as many cancer spots as a commonly used PSMA PET scan in men whose prostate-specific antigen (PSA) was rising after ...
Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until ...
New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from ...
The recurrence of prostate cancer can now be detected 14.8 months sooner than existing clinical practices with new technology developed by a professor at Purdue University in West Lafayette, Ind. The ...
To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department of Radiation ...
SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...
Adding apalutamide to androgen deprivation therapy prolonged prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer in the phase 3 PRESTO trial.
In the article that accompanies this editorial, Aggarwal et al 8 found that 1 year of intensified androgen deprivation therapy (ADT) prolongs the time to next prostate-specific antigen progression (or ...
A Purdue University mechanical engineer and his international collaborators have developed a patent-pending method and algorithm to predict the recurrence of prostate cancer in patients treated by ...
Longer time to relapse is associated with a decreased risk of dying from prostate cancer. PSA recurrence (PSAR) more than five years after radical prostatectomy for prostate cancer is associated with ...